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National Rules for Drug–Drug Interactions: Are They Appropriate 
for Tertiary Hospitals?
The application of appropriate rules for drug–drug interactions (DDIs) could substantially 
reduce the number of adverse drug events. However, current implementations of such 
rules in tertiary hospitals are problematic as physicians are receiving too many alerts, 
causing high override rates and alert fatigue. We investigated the potential impact of 
Korean national DDI rules in a drug utilization review program in terms of their severity 
coverage and the clinical efficiency of how physicians respond to them. Using lists of high-
priority DDIs developed with the support of the U.S. government, we evaluated 706 
contraindicated DDI pairs released in May 2015. We evaluated clinical log data from one 
tertiary hospital and prescription data from two other tertiary hospitals. The measured 
parameters were national DDI rule coverage for high-priority DDIs, alert override rate, and 
number of prescription pairs. The coverage rates of national DDI rules were 80% and 3.0% 
at the class and drug levels, respectively. The analysis of the system log data showed an 
overall override rate of 79.6%. Only 0.3% of all of the alerts (n = 66) were high-priority 
DDI rules. These showed a lower override rate of 51.5%, which was much lower than for 
the overall DDI rules. We also found 342 and 80 unmatched high-priority DDI pairs which 
were absent in national rules in inpatient orders from the other two hospitals. The national 
DDI rules are not complete in terms of their coverage of severe DDIs. They also lack clinical 
efficiency in tertiary settings, suggesting improved systematic approaches are needed.
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INTRODUCTION
A drug–drug interaction (DDI) alert is a type of medication-re-
lated clinical decision support function in a computerized pro-
vider order entry (CPOE) system. These alerts provide the prom-
ise of substantially reducing the number of adverse drug events 
(ADEs) by introducing automation at the time of ordering and 
by rapidly supplying usable prescribing algorithms (1). Howev-
er, implementations of DDI alerts do not always provide the an-
ticipated benefits. They can be very difficult to optimize, and 
alert fatigue can be a major problem if too many false-positive 
warnings are delivered (2).
 Since December 2010, Korean hospitals have been required 
to provide DDI alerts to physicians using the prospective drug 
utilization review (DUR) system run by the Health Insurance 
Review Agency (HIRA) (3-5). This DUR system aims to provide 
quality assurance and ensure the provision of appropriate drug 
therapies, and it was designed to prevent potential ADEs aris-
ing from medication errors and inappropriate drug use (3,5). 
The national DDI rule set was initiated and included 162 DDI 
combinations and up to 706 contraindicated co-prescription 
pairs as of August 2015.
 While DDI alerts can reduce the number of DDI-related ADEs, 
alert fatigue induced by large numbers of DDI alerts can also 
lead to physicians ignoring clinically significant DDI alerts (2,6-
8). A recent review of empirical analyses of CPOEs with the na-
tional DDI rules found that physicians in general hospitals over-
rode a substantial fraction of automated warnings, with one 
study finding that physicians continuing with prescription or-
ders in 72.2% of DDI cases (9). One study of DDI alert logs re-
vealed a high override rate of 72.8% at a tertiary hospital, even 
the authors just considered a new alert regarding a DDI during 
18 months of observation period (10). Our previous examina-
tion of DDI alert logs revealed a high override rate of 83% at a 
tertiary hospital (8). According to a report which analyzed HIRA 
DUR data, the override rates for DDI alerts were 76.6% in 2012 
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and 78% in 2013 (11). Such high override rates have prompted 
serious concerns that physicians may be overriding or ignoring 
clinically important warnings, which potentially has major im-
plications both for safety and physician liability. The alerts may 
be unnecessarily interrupting physicians, which could threaten 
the provision of a consistent work process and cause inefficient 
use of time and other resources (12).
 In an attempt to address this problem, the present study in-
vestigated the national DDI rules using three approaches. The 
first approach involved comparing the Korean DDI rules with a 
list of the most dangerous DDIs. These lists, known as high-pri-
ority DDI rules, were identified by a sponsor of the Office of the 
National Coordinator for Health Information Technology in the 
USA (13,14). It is a set of 15 high-severity, clinically significant 
DDIs were identified for which it was advised that warnings 
should be generated in all electronic health record systems. The 
second approach involved investigating the DDI alert log data 
of a tertiary hospital to identify the rates at which high-priority 
DDI rules are alerted and overridden in practice. We also com-
pared the results with those obtained at three hospitals in Bel-
gium, the UK, and the USA. The third approach involved exam-
ining medication orders from two other hospitals in order to 
determine whether unmatched high-priority DDI rules appear 
in prescriptions. Based on the obtained results, we describe sev-
eral areas that need further investigation in order to achieve the 
successful application of DDI alerts.
MATERIALS AND METHODS
We compared the current Korean national DDI rules with the 
lists of high-priority DDI rules found in previous studies (13). 
To identify the differences, we use a comparison framework (Fig. 
1). A retrospective observational design was used to analyze the 
alert system logs. Fig. 2 shows the study procedure, materials, 
measurements, and participating hospitals. We investigated data 
from three Korean hospitals: data from one hospital were used 
for analyzing alert log data, and the data from the other two were 
used for analyzing prescription data. The intercountry analyses 
compared the performance of national DDI rules in South Ko-
rea with those of hospitals in three other countries. In this study 
Fig. 1. Comparison framework of the Korean national drug–drug interaction (DDI) 
rules and the USA high-priority DDI rules.
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we included a part of results of another study involving three of 
the authors (I.C., J.H.L., and D.W.B.) (8).
Korean national DDI rules and lists of high-priority DDIs 
in the USA
The national DDI rules were developed based on the product 
labeling information provided by the Korea Food and Drug Ad-
ministration and maintained by the HIRA. The list of high-pri-
ority DDIs consists of 15 drug class interactions that meet strin-
gent criteria indicating that those drugs should never be pre-
scribed together. The list comprises 2,563 drug pairs, including 
2,162 possible pairs of QT-prolonging agents (involving 47 drugs). 
These pairs were identified on a consensus basis by expert pan-
elists, who included medication knowledge-base vendors, elec-
tronic medical record (EMR) vendors, in-house knowledge-base 
developers from academic medical centers, and both federal 
and private agencies involved in the regulation of medication 
use in the USA (13). The panel assigned severity levels to the in-
teractions based on information in various medication knowl-
edge bases, and assessed the consequences of the interactions, 
the availability of therapeutic alternatives, monitoring and man-
agement options, predisposing factors, and the probability of 
the interactions occurring based on the strength of evidence 
available in the literature (13).
Settings and data sources
The Korean sites comprised three tertiary teaching hospitals 
having computerized physician order entry (CPOE) systems 
and complete in-house-designed EMR systems since 2003 or 
2005. The systems were used throughout the hospitals by all 
physicians working in both inpatient and outpatient settings. 
The hospitals instituted DDI checking as a decision-support 
component of the CPOE system with at least the following four 
different types of alerts from the national DUR program: drug 
allergy, duplication, pregnancy contraindication, and drug for-
mulary. These alerts were implemented based on the drug list 
released by the HIRA.
 The systems log in one of the hospitals was used to track the 
interactions between the DDI alerts and physicians. The log was 
designed to record a patient who had received medications, a 
drug combination order that triggered an alert, the physician 
who ordered the prescriptions, the acceptance status of the alert, 
and any reason(s) for overriding the alert, which were coded 
options or entered with free text. We collected the log data for 
four consecutive months, from September 1 to December 31, 
2014. The data contained 18,360 and 3,499 alert records for in-
patient and outpatient settings, respectively. The results of a more 
detailed analysis of the system log data by our team will be pre-
sented in a future report.
 The other two hospitals were involved in the third approach 
of this study: assessing the frequencies of drug orders correspond-
ing to unmatched high-priority DDI rules. We retrospectively 
collected medication orders related to 210 and 220 patients who 
were discharged in 2013. The patients were stratified equally 
into medical-surgical units and intensive-care units, which in-
volved the review of 55,244 and 14,925 prescriptions, respec-
tively. Because these two hospitals did not have DDI alert log 
data, they were not included in system log analysis. The hospi-
tal that had alert log data did not participated in prescription 
data analysis due to its internal policy. To get recent DDI rules, 
alert log data of 2014 were analyzed. So study periods of the for-
mer hospital and the other two hospitals were not the same.
 Intercountry comparisons were performed based on the anal-
ysis results for the log data from the three hospitals in the UK, 
the USA, and Belgium (8). Table 1 summarizes the information 
for the sites. They were all tertiary teaching hospitals and had 
their own DDI rules with severity levels that were developed 
using in-house approaches. The UK and USA sites had two and 
three levels of severity: hard stop, interruptive, and non-inter-
ruptive.
Measurements
Based on our study design diagram (Fig. 2), the primary out-
comes of this study were the national DDI rule coverage rate for 
high-priority DDI lists and the override rates as obtained from 
analyses of system logs. The secondary outcome was the num-
ber of medication prescriptions that were not included in the 
national DDI rules but which were corresponded to the high-
priority DDI list.
Data analysis
Descriptive statistics were used to summarize the rate of rule 
Table 1. Characteristics of the hospitals involved in this study
Characteristics Korea Belgium UK USA
Period of time coverage 4 mon (Sep.-Dec. 2014) 1 yr (Jan.-Dec. 2011) 1 yr (Jan.-Dec. 2011) 3 yr (2009-2011)
Hospital type Tertiary teaching hospital Tertiary teaching hospital Tertiary teaching hospital Tertiary teaching hospital
Clinical setting Inpatient and outpatient Inpatient Inpatient Outpatient 
DDI rule knowledge base National rules Commercial rules Self-developed rules Self-developed rules
Priority system for DDI rules No levels  
(all rules are interruptive)
6 levels (trigger alerts only  
for level 1 and 2)
2 levels (hard stop,  
& interruptive)
3 levels (hard stop, interruptive,  
& non-interrupted)
DDI = drug-drug interaction.
Cho I, et al. • Appropriateness of National Drug–Drug Interaction Rules
1890  http://jkms.org https://doi.org/10.3346/jkms.2016.31.12.1887
Table 2. Cross-matching the national DDI rules with the list of high-priority DDI rules
Rule No.*
List of high-priority DDI rules National DDI rules
Object drug/class Precipitant drug/class No. of final pairs No. of matched rules
No. of unmatched  
national rules
  3 Amphetamine and derivatives MAO inhibitors 60 6 54
  4 Atazanavir PPI 5 4 1
  5 Febuxostat Azathioprine/mercaptopurine 2 0 2
  8 SSRIs MAO inhibitors 55 4 51
11 Irinotecan Strong CYP3A4 inhibitors 24 1 23
16 Narcotic analgesics MAO inhibitors 30 3 27
20 TCAs† MAO inhibitors 40 5 35
21 QT-prolonging agents‡ QT-prolonging agents‡ 2,162 17 2,145
22 Ramelteon CYP1A2 inhibitors 4 0 4
23 Strong CYP3A4 inhibitors Protease inhibitors 60 2 58
25 HMG Co-A reductase inhibitors CYP3A4 inhibitors 38 12 26
27 CYP3A4 inhibitors Ergot alkaloids and derivatives 60 22 38
28 Tizanidine CYP1A2 inhibitors 7 1 6
30 Tranylcypromine Procarbazine 1 0 1
31 Triptans MAO inhibitors 15 1 14
No. of class-pairs: 15 (100.0%)    No. of matched class-pairs 12 (80.0%)
    No. of drug-pairs: 2,563 (100.0%) No. of matched drug-pairs 78 (3.0%)
DDI = drug-drug interaction, PPI = proton-pump inhibitors, SSRI = selective serotonin reuptake inhibitors, MAO = monoamine oxidase, TCAs = tricyclic antidepressants.
*Rule number in (13); †List of TCAs: Mayo Clinic, http://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983?pg = 2; ‡QT-prolonging 
agents: https://www.crediblemeds.org (accessed May 15, 2015).
Table 3. Numbers of alerts and override rates of matched high-priority DDI rules
Rule No.* Object-drug–precipitant-drug pair
No. of 
alert
No. of overrides 
(override rate, %)
  8 Fluvoxamine–selegiline   3 3 (100)
16 Tramadol–selegiline   7 1 (14.3)
20 Amitriptyline–selegiline   2 1 (50)
21 Amiodarone–dronedarone   9 6 (66.7)
Amiodarone–sotalol 30 14 (46.7)
25 Simvastatin–clarithromycin/itraconazole 15 9 (60.0)
No. of drug class-pairs: 5/12 (41.7%) 66 34 (51.1)
No. of drug-pairs fired alerts: 6/78 (7.7%)
DDI = drug-drug interaction.
*Rule number in (13).
coverage, the rate of alert overrides, and the number of medica-
tion prescriptions. We compared the rule coverage and alert 
override rates among hospitals according to the high-priority 
DDI rules. The comparison results are presented as counts with 
percentage values and probability values obtained in the χ2 test. 
We used SAS software (version 9.3, SAS Institute, Cary, NC, USA) 
for the analyses.
Ethics statement
This study was conducted with the approval of the institutional 
review board at each hospital. (Asan Medical Center, IRB: 2014-
1101) Informed consent was not required because the review of 
retrospective DDI alert logs and prescriptions did not involve 
individually identifiable data of any sort.
RESULTS
National DUR rule coverage for high-priority DDI lists of 
the USA
The national DDI rules included 78 (3.0%) drug pairs of high-
priority DDI rules (2,563). Drug class pairs constituted 12 (80%) 
of the 15 rule categories in the national rules (Table 2). The three 
categories of febuxostat—azathioprine/mercaptopurine, ramelt-
eon—CYP1A2 inhibitors, and tranylcypromine—procarbazine 
were not found in the national DDI rules. For QT-prolonging 
agents and tricyclic antidepressants (TCAs) that suggested drug 
classes rather than explicit drugs, we considered only 47 drugs 
classified in the high-risk category among QT-prolonging agents 
and 8 TCAs. We found only 17 QT-prolonging agent pairs in the 
list of national DDIs (Appendix 1).
Override rates of matched DDI rules
The review of 21,859 alerts revealed that only 6 rules out of 78 
matched rules which are both in national rules and high-priori-
ty rules triggered 66 alerts. This represented only 0.3% (66/21,859) 
of all of the alerts presented to physicians. The average overall 
override rate of the 66 alerts was 51.5% (ranging from 14.3% to 
100%) (Table 3), and the overall DDI override rate was 79.6% in 
both the inpatient and outpatient settings. The pairs of QT-pro-
longing agents constituted the most frequently alerted drug pairs, 
while fluvoxamine-selegiline (amphetamine and derivatives–
MAO [monoamine oxidase] inhibitors) and simvastatin-clar-
ithromycin/itraconazole (HMG Co-A reductase inhibitors–pro-
tease inhibitors) were the pairs that were most frequently over-
ridden by physicians.
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Table 5. Prescriptions containing high-priority DDI pairs of unmatched rules
Rule No.* High-priority DDI pair (object–precipitant class/drug) No. of unmatched rules
No. of prescriptions
Hospital A Hospital B
21 QT-prolonging agents–QT-prolonging agents† 2,145 320 80
22 Ramelteon–CYP1A2 inhibitors 4 3 0
25 HMG Co-A reductase inhibitors–CYP3A4 inhibitors 23 19 0
Total 342 80
DDI = drug-drug interaction.
*Rule number in (13); †https://www.crediblemeds.org (accessed May 15, 2015).
Table 4. Comparison of the coverage of high-priority DDI rules, and override rates in 
hospitals in four countries
Measurement  
   Hospital
Class-level coverage 
(no. of class-
pairs = 15)
Rule coverage  
(no. of drug-
pairs = 2,563)
Override  
rate (%)
Korea 12   78 51.1
Belgium 14 611 74.9
UK 10 131 83.3
US 11 113 56.6
DDI = drug-drug interaction.
Intercountry comparison of coverage for high-priority 
DDI rules
In the intercountry comparison, the UK and USA hospitals in-
cluded 10 and 11 class-pairs, respectively (Table 4). The rules at 
the Belgium hospital corresponded for 14 out of 15 class-pairs. 
Rule coverage at the drug level ranged from 3.0% (78/2,563) in 
Korea to 23.8% (611/2,563) in Belgium, and was 5.1% (131/2,563) 
at the UK hospital and 4.4% (113/2,563) at the USA hospital. The 
override rate of high-priority DDI rules was highest for the UK 
hospital, at 83.3%, followed by the Belgium hospital (74.9%), the 
USA hospital (56.6%), and the Korean hospital (51.5%).
Prescriptions unmatched high-priority DDI pairs
The analysis of medication prescriptions examined whether the 
unmatched high-priority DDI pairs which were absent in na-
tional rules were prescribed and how many there were. At one 
hospital there were 342 drug pairs among 55,244 prescriptions 
(0.6%) (Table 5), while another hospital had 80 drug pairs among 
14,925 prescriptions (5.4%). Most of them were QT-prolonging 
agent pairs, and there were no pairs overlapping between the 
two hospitals. The class/drug pairs of ramelteon—CYP1A2 in-
hibitors and HMG Co-A reductase inhibitor—CYP3A4 inhibi-
tors were observed 3 and 19 times, respectively, at 1 hospital.
DISCUSSION
We found that the national rules coverage rate for high priority 
DDI rule was 3.0%, which was low given that there were 706 con-
traindicated rules. These matched high-priority DDI rules that 
triggered 0.3% of the alerts that the physicians had received, and 
these showed a lower override rate than the overall override rate. 
The proportion of high-priority DDI rules among the Korean 
national rules was lower than for those of the UK and USA. We 
also found noticeable numbers of unmatched high-priority DDI 
pairs in prescriptions in two inpatient settings, which may be 
associated with medication safety risks.
 The national rules included 80% of the high-priority DDI rules 
at the class level, but omitted most of the possible high-priority 
DDI pairs. These findings imply that the national rules include 
sufficient drug classes for high-priority DDI rules but are defi-
cient at the drug level, even though the total number of rules 
exceeded 700. We can think of two reasons for this situation. 
The first is that unmatched high-priority DDI pairs are not pre-
scribed by physicians in Korea, perhaps due to their good edu-
cation or training. However, our findings of noticeable numbers 
of unmatched high-priority DDI pairs in prescriptions for inpa-
tients make this hypothesis unlikely. In addition, the small de-
gree of overlap of the unmatched rules between the two hospi-
tals suggests that investigating different hospitals could reveal 
different unmatched high-priority DDI pairs. Therefore, this 
might not due simply to the availability in a drug formulary at 
each site. The second possibility is that the expert committee of 
HIRA did not consider the unmatched high-priority DDI rules. 
If that is the case, the unmatched rules should be considered 
first for inclusion in the national rules. The level of risks of the 
moderate-priority DDI rules then needs to be considered. We 
doubt that DDI rules with a moderate level of risk are appropri-
ate in all circumstances, such as “always contraindicated DDIs,” 
but such a list would be of limited usefulness because it could 
not adequately reflect the clinical complexity of many treatment 
decisions, especially in tertiary hospitals. The risk of DDIs often 
varies from patient to patient, potentially being influenced by 
factors such as age, sex, kidney function, liver function, genetic 
makeup, and diseases, as well as the dose and route of admin-
istration of the medication (15-17).
 Our previous investigation of the appropriateness of DDI alert 
overrides by physicians based on a review of patient EMRs re-
vealed that 68.2% of the DDI alert overrides were considered 
appropriate (2). This relative high rate of appropriateness im-
plies that simple checking of prescription drug lists could have 
limitations, because this would not consider the clinical context 
and patient-specific information. Adapting rules based on pa-
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tient-specific information could improve the clinical sensitivity 
of DDI rules and alerts.
 Considering the matched high-priority DDI rules, only 7 rules 
triggered 66 alerts, which represented only 0.3% (66/21,889) of 
all alerts, and physicians responded to many of these. The over-
ride rate of 51.5% is lower than the overall override rate of 79.6%, 
but none of these alerts should actually have been overridden. 
This result implies that physicians rarely prescribe drugs involv-
ed in high-priority DDIs together, and when they receive alerts 
related to high-priority DDI rules they are more willing to ac-
cept them. Therefore, including more high-priority DDI rules in 
the national rules might improve the override rate and relieve 
alert fatigue, as well as reduce interruptions to the work flow of 
physicians and time-wasting. In addition, organizations might 
want to consider “hard stops” so that for the very most severe of 
these, the drugs cannot be ordered together.
 The national DDI rules were developed by a process in which 
the DDIs to be avoided were determined, and involved experts 
representing various professional organizations (1). However, it 
should be remembered that there is considerable debate about 
the scientific evidence for the risk that many DDIs pose to pa-
tients (13). DDI information can be obtained from a various 
sources, but the data are often inconsistent or unreliable. One 
study of 458 drug pairs found that proprietary databases rated 
7.4% of interactions (34/458) as severe while clinicians assessed 
6.6% (30/458) as severe; this looks promising, but unfortunately 
only 3 of the interactions were considered severe according to 
both the databases and clinicians (18). Another study found that 
a panel of experts initially agreed on the clinical significance of 
particular DDIs approximately 50% of the time (19). The com-
parison of high-priority DDI rules using log data obtained in 
different countries revealed that even though the coverage of 
high-priority DDI rules is lower in Korea than in the other in-
vestigated countries, the override rates in Korea was similar with 
that of USA, and were much lower than those in UK and Bel-
gium. This finding implies that Korean physicians responded 
more likely to accept the alerts of high-priority rules.
 We also noticed that the two categories of QT-prolonging agent 
pairs and the HMG Co-A reductase inhibitors–CYP3A4 inhibi-
tors showed the greatest differences among countries. The Bel-
gium hospital had the largest number of rules for those pairs, 
but also had a low alert frequency. In contrast, the USA hospital 
had smaller numbers of such pairs but the largest numbers of 
alerts with a very low override rate compared to Belgium. The 
UK hospital had QT-prolonging agents rule, but these inactivat-
ed in their system, and only five rules were present for HMG 
Co-A reductase inhibitors–CYP3A4 inhibitors, with no cases of 
alerts. The Korean national rules contained small numbers of 
those pairs with much smaller alert frequencies, but higher over-
ride rates than in the USA. We did not know whether or not the 
high override rate was due to the Korean national rules having 
smaller rule sets for these class-pairs. However, based on the 
frequency analysis of drug pairs that were not matched with high-
priority DDI rules in prescriptions, it is likely that appropriate 
rules were missing.
 Our examination of unmatched high-priority DDI pairs in 
prescriptions showed that significant numbers of drug combi-
nations were prescribed. Most of the combinations were QT-
prolonging agent pairs, and they constituted 0.5%-0.6% of the 
total prescriptions at two of the hospitals. For the categories of 
rifampin–ritonavir and HMG Co-A reductase inhibitors–prote-
ase inhibitors, only small numbers of prescriptions were observ-
ed in one hospital. Although these are small proportions, they 
are potentially associated with high DDI risks and their conse-
quences could be serious or even fatal; they therefore need to 
be considered for incorporation in the national rules.
 In summary, the Korean national rules are shortcoming in 
coverage of contraindications of high-priority rules, which could 
be responsible for problems of a high override rate and alert fa-
tigue associated with physician liability. When we assessed the 
rate of overrides by physicians, about 15% of them (80/529) re-
ceived more than 20 DDI alerts during the 4-month analysis 
period and overrode all of them; that is, an override rate of 100%. 
The reason we used the frequency of 20 DDI alerts during the 
period, was to exclude the miss classification of physicians with 
small number of alerts having relatively high override opportu-
nity. The 100% override was both unexpected and undesirable, 
which demonstrates the need to consider several aspects such 
as the provision of too many unnecessary interruptions and an 
inadequate consideration of liability. Our findings also identi-
fied several possible ways for minimizing the alert fatigue asso-
ciated with the national rules in tertiary hospitals, including strat-
egies to increase their sensitivity and relevancy. These sugges-
tions involve both government and local hospitals. First, it would 
actually be unreasonable to expect one set of rules to fit all hos-
pitals due to the diversity of patients with vastly different types 
of illnesses and levels of severity. An approach based on the DDI 
priority level would be easier than one based on patient severi-
ty, because of a lack of measurements, tools, and interrater reli-
ability. For example, high-priority DDI rules could be consid-
ered for all hospitals with a hard stop or interruptive, while mod-
erate-priority DDI rules would be presented as being optional 
or informative in tertiary hospitals (4).
 Second, DDI warnings should provide concise but compre-
hensive information that will enable physicians to make more 
knowledgeable and effective prescribing decisions (4). The cur-
rent simple lists of DDI combinations that are typically used can 
be misleading, as they do not address clinical complexity or the 
highly individualized nature of many treatment choices. Such 
information could include alternative drugs, ways to adjust pa-
tient monitoring, and general background information such as 
evidence of DDIs, the clinical relevance of the possible adverse 
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DDI consequences, specific risk factors, and the incident rate of 
adverse reactions.
 Third, to improve the rule sensitivity, each hospital could uti-
lize patient data stored in their own EMR systems for determin-
ing when DDI warnings will be issued. Both the risk of an ad-
verse drug reaction due to a DDI and the quality of the evidence 
concerning that risk may depend on multiple patient-specific 
risk factors, some or even all of which may be recorded in the 
EMR of a patient. The reliability of DDI alerts will then depend 
on the accuracy of the data in EMRs, which may be compromis-
ed by input errors, omissions, and incomplete entries. One re-
search reported that adding clinical laboratory values, concom-
itant medication, patient demographics, and administration 
time to basic DDI checking algorithm results in a 55% reduction 
of the number of alerts and a 45% reduction in time spent on 
DDI checking, yielding a return on investment of almost 10 years 
(20). Also, before being deployed, the rules should be piloted in 
several representative settings to determine whether they are 
effective in improving prescribing decisions and are not overly 
disruptive to physicians. Additional or revised rules could be 
incorporated in the prescribing process through a similar pro-
cess. These processes could be undertaken by the HIRA.
 This study was subject to several limitations. First, practice 
log and prescription data obtained from three tertiary teaching 
hospitals were used, and so the results might not be generaliz-
able to other tertiary general hospitals. However, the national 
rules are mandatory and they are used nationwide in all prima-
ry, secondary, and tertiary hospitals. Moreover, our findings 
were consistent with those in other literature and relevant re-
ports. We also compared our findings in the present study with 
findings that we obtained in other countries in previous studies. 
Second, we did not evaluate the appropriateness of the alerts 
that were overridden and could not follow up the patient out-
comes in the overridden cases; further research is therefore need-
ed in order to optimize the national DDI rules.
 The current national DDI rules of HIRA are not complete in 
terms of their severity coverage. They also have considerable 
shortcomings in clinical efficiency in tertiary settings, which in-
dicates the need for improved systematic approaches (21). To 
improve safety and reduce alert fatigue, the national rules should 
be improved by setting up a process of monitoring and refine-
ment of the list, establishing tests and validation processes be-
fore releasing them, empowering physicians by providing them 
with concise and comprehensive information, and using a so-
phisticated design that is integrated with the patient data avail-
able in EMR systems.
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Appendix 1. Detailed information of Cross-matching the national DDI rules with the list of high-priority DDI rules
List of high-priority rules National DDI rules
C andidate DDI pair:  
Object-precipitant drug/
class (No. of final DDI 
pairs)
Matched Unmatched
Object drug/class Precipitant drug/class
No. of  
pair
Object drug/class Precipitant drug/class
No. of  
pair
Amphetamine and deriva-
tives–MAO inhibitors 
(60)
Atomoxetine
Methylphenidate
Pseudoephedrine
Diethylpropion
Phendimetrazine
Phentermine 
Selegiline 6 Dexmethylphenidate
Dextroamphetamine
Lisdexamefetamine
Methamphetamine
Amphetamine
Benzphetamine
6 object drugs of matched rules
Tranylcypromine
Phenelzine
Isocarboxazid
Procarbazine
Selegiline
54
Atazanvir–PPI (5) Atazanavir Esmoprazole
Lansoprazole
Pantoprazol 
Rabeprazole
4 Atazanavir Omeprazole 1
Febuxostat–azathioprine/
mercaptopurine (2)
- - 0 Febuxostat Azathioprine
Mercaptopurine 
2
SSRIs–MAO inhibitors (55) Fluoxetine
Fluvoxamine
Sertraline
Venlafaxine 
Selegiline 4 Citalopram
Escitalopram
Duloxetine
Nefazodone
Desvenlafaxine
Milnacipran
4 object drugs of matched rules
Tranylcypromine
Phenelzine
Isocarboxazid
Procarbazine
Selegiline
51
Irinotecan–Strong  
CYP3A4 inhibitors  
(24)
Irinotecan Atazanavir 1 Irinotecan Ritonavir
Nelfinavir
Indinavir
Saquinavir
Amprenavir
Darunavir
Lopinavir
Tipranavir
Fosamprenavir
Saquinavir
Clarithromycin
Erythromycin
Telithromycin
Amiodarone
Verapanil
Diltiazem
Ketoconazole
Itraconazole
Fluconazole
Voriconazole
Nefazodone
Aprepitant
Cimetidine
23
Narcotic analgesics– 
MAO inhibitors (30)
Meperidine
Tramadol
Dextromethorphan 
Selegiline 3 Methadone
Tapentadol
Fentanyl
3 object drugs of matched rules
Tranylcypromine
Phenelzine
Isocarboxazid
Selegiline
Procarbazine
27
TCAs*–MAO inhibitors 
(40)
Amitriptyline
Amoxapine
Imipramine
Nortriptyline
Doxepin
Selegiline 5 8 object drugs
3 object drugs
Tranylcypromine
Phenelzine
Isocarboxazid
Procarbazine
Selegiline
35
QT prolonging agents‡–
QT prolonging agents‡ 
(2,162)
Amiodarone–Sotalol/Sparfloxacin/Dronedarone/
Erythromycin/Pentamidine/Pimozide/Quinidine
17 QT prolonging agents†–QT prolonging agents† 2,145
Pimozide–Erythromycin/Escitalopram/Citalo-
pram/Clarithromycin/Dronedarone/Quinidine
Quinidine–Azithromycin/Fluconazole/Clarithro-
mycin/Erythromycin
(Continued to the next page)
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List of high-priority rules National DDI rules
C andidate DDI pair:  
Object-precipitant drug/
class (No. of final DDI 
pairs)
Matched Unmatched
Object drug/class Precipitant drug/class
No. of  
pair
Object drug/class Precipitant drug/class
No. of  
pair
Ramelteon–CYP1A2  
inhibitors (4)
- - 0 Ramelteon Fluvoxamine
Amiodarone
Ticlopidine
Ciprofloxacin 
4
Strong CYP3A4 inhibitors-
protease inhibitors (60)
Rifampin Indinavir
Nelfinavir
2 Bosentan
Rifapentine
Carbamazepine
Rifabutin
St John’s wort
Ritonavir
Amprenavir
Darunavir
Fosamprenavir
Lopinavir
Saquinavir
Tipranavir
2 precipitant drugs matched rules
58
HMG Co-A reductase  
inhibitors–CYP3A4  
inhibitors (38)
Simvastatin
Lovastatin
Nelfinavir
Darunavir
Telithromycin
Clarithromycin
Ketoconazole
Itraconazole
12 Simvastatin
Lovastatin
Saquinavir
Tipranavir
Ritonavir
Atazanavir
Amprenavir
Lopinavir
Erythromycin
Amidarone
Verapamil
Diltiazem
Fluconazole
Voreconazole
Nefazodone
26
CYP3A4inhibitors–ergot 
alkaloids and  
derivatives (60)
Erythromycin
Indinavir
Itraconazole
Nelfinavir
Ritonavir
Voriconazole
Ritonavir
Clarithromycin
Lopinavir
Telithromycin
Atazanavir
Darunavir
Ergotamine 
Methylergonovine
Dihydroergotamine
22 Saquinavir
Tipranavir
Amprenavir
Ketoconazole
12 object drugs of matched rules
Ergotamine 
Methylergonovine
Dihydroergotamine
Ergonovine
38
Tizanidine–CYP1A2  
inhibitors (7)
Tizanidine Fluvoxamine 1 Tizanidine Ciprofloxacin
Mexiletine
Propafenone
Zileuton
Amiodarone
Ticlopidine
6
Tranylcypromine–procar-
bazine (1)
- - 0 Tranylcypromine Procarbazine 1
Triptans–MAO inhibitors 
(15)
Zolmitriptan Moclobemide 1 Zolmitriptan
Sumatriptan
Rizatriptan 
Moclobamide 
Tranylcypromine
Phenelzine
Isocarboxazid
Methylene blue 
14
DDI = drug–drug interaction, SSRI = selective serotonin reuptake inhibitors, MAO = monoamine oxidase, PPI = proton-pump inhibitors, TCAs = tricyclic antidepressant.
*List of TCAs: Mayo Clinic, http://www.mayoclinic.org/diseases-conditions/depression/in-depth/antidepressants/art-20046983?pg = 2; †Cross-matching the national DDI rules 
with the list of high-priority DDI rules https://www.crediblemeds.org (accessed May 15, 2015).
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